CoChat
Sign Up
Cited by 15Mesenchymal stem cell researchHematopoietic Stem Cell TransplantationLiver physiology and pathology

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Clinical application of stem cell in patients with end-stage liver disease: progress and challenges

Open access
Tao, Ya-Chao, Chen, En-Qiang·2020·Annals of Translational Medicine
DOI 10.21037/atm.2020.03.153PMC PMC7347777
Open this paper in CoChat — free accountOpen PDF

Abstract

End-stage liver disease (ESLD) is life-threatening disease worldwide, and patients with ESLD should be referred to liver transplantation (LT). However, the use of LT is limited by the lacking liver source, high cost and organ rejection. Thus, other alternative options have been explored. Stem cell therapy may be a potential alternative for ESLD treatment. With the potential of self-renewal and differentiation, both hepatic and extrahepatic stem cells have attracted a lot of attention. Among them, multipotent stem cells are most widely studies owing to their characteristics. Multipotent stem cells mainly consist of two subpopulations: hematopoietic stem cells (HSCs) and mesenchymal stem cells (MSCs). Accumulating evidences have proved that either bone marrow (BM)-derived HSCs mobilized by granulocyte colony-stimulating factor or MSCs transplantation can improve the biochemical indicators of patients with ESLD. However, there are some challenges to be resolved before stem cells widely used in clinic, including the best stem cell source, the optimal route for stem cells transplantation, and the dose and frequency of stem cell injected. The purpose of this review is to discuss the potential of stem cell in liver diseases, particularly, the clinical progress and challenges of multipotent stem cells in the field of ESLD.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.21037/atm.2020.03.153

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 70

  1. [1]Terai S Sakaida I. Current status of autologous bone marrow cell infusion therapy for liver cirrhosis patients. Hepatol Res 2008; 38 Suppl 1: S72- 75. 10.1111/j.1872-034X.2008.00430.x 19125956 · DOI
  2. [2]Rehman K Iqbal MJ Zahra N Akash MS. Liver stem cells: From preface to advancements. Curr Stem Cell Res Ther 2014; 9: 10- 21. 10.2174/1574888X113086660066 24090240 · DOI
  3. [3]Kordes C Haussinger D. Hepatic stem cell niches. J Clin Invest 2013; 123: 1874- 80. 10.1172/JCI66027 23635785 PMC3638908 · DOI
  4. [4]Van Haele M Roskams T. Hepatic progenitor cells: An update. Gastroenterol Clin North Am 2017; 46: 409- 20. 10.1016/j.gtc.2017.01.011 28506372 · DOI
  5. [5]Pan XR Jing YY Liu WT Lipopolysaccharide induces the differentiation of hepatic progenitor cells into myofibroblasts via activation of the hedgehog signaling pathway. Cell Cycle 2017; 16: 1357- 65. 10.1080/15384101.2017.1325976 28562206 PMC5539817 · DOI · Paper page
  6. [6]Sekiya S Miura S Matsuda-Ito K Myofibroblasts derived from hepatic progenitor cells create the tumor microenvironment. Stem Cell Reports 2016; 7: 1130- 9. 10.1016/j.stemcr.2016.11.002 27916538 PMC5161752 · DOI
  7. [7]Houlihan DD Newsome PN. Critical review of clinical trials of bone marrow stem cells in liver disease. Gastroenterology 2008; 135: 438- 50. 10.1053/j.gastro.2008.05.040 18585384 · DOI
  8. [8]Tolosa L Caron J Hannoun Z Transplantation of HESC-derived hepatocytes protects mice from liver injury. Stem Cell Res Ther 2015; 6: 246. 10.1186/s13287-015-0227-6 26652177 PMC4676869 · DOI
  9. [9]Woo DH Kim SK Lim HJ Direct and indirect contribution of human embryonic stem cell-derived hepatocyte-like cells to liver repair in mice. Gastroenterology 2012; 142: 602- 11. 10.1053/j.gastro.2011.11.030 22138358 · DOI
  10. [10]Peterson SE Loring JF. Genomic instability in pluripotent stem cells: Implications for clinical applications. J Biol Chem 2014; 289: 4578- 84. 10.1074/jbc.R113.516419 24362040 PMC3931019 · DOI
  11. [11]Nantasanti S de Bruin A Rothuizen J Concise review: Organoids are a powerful tool for the study of liver disease and personalized treatment design in humans and animals. Stem Cells Transl Med 2016; 5: 325- 30. 10.5966/sctm.2015-0152 26798060 PMC4807664 · DOI
  12. [14]Tolosa L Pareja E Gomez-Lechon MJ. Clinical application of pluripotent stem cells: An alternative cell-based therapy for treating liver diseases? Transplantation 2016; 100: 2548- 57. 10.1097/TP.0000000000001426 27495745 · DOI
  13. [15]Esrefoglu M. Role of stem cells in repair of liver injury: Experimental and clinical benefit of transferred stem cells on liver failure. World J Gastroenterol 2013; 19: 6757- 73. 10.3748/wjg.v19.i40.6757 24187451 PMC3812475 · DOI
  14. [16]Mosaad YM. Hematopoietic stem cells: An overview. Transfus Apher Sci 2014; 51: 68- 82. 10.1016/j.transci.2014.10.016 25457002 · DOI
  15. [17]Dalakas E Newsome PN Harrison DJ Hematopoietic stem cell trafficking in liver injury. Faseb J 2005; 19: 1225- 31. 10.1096/fj.04-2604rev 16051689 · DOI
  16. [18]Ahmadi AR Chicco M Wesson RN Stem cell mobilization is lifesaving in a large animal preclinical model of acute liver failure. Ann Surg 2018; 268: 620- 31. 10.1097/SLA.0000000000002958 30102635 · DOI
  17. [19]Gaia S Smedile A Omede P Feasibility and safety of G-CSF administration to induce bone marrow-derived cells mobilization in patients with end stage liver disease. J Hepatol 2006; 45: 13- 9. 10.1016/j.jhep.2006.02.018 16635534 · DOI
  18. [20]Duan XZ Liu FF Tong JJ Granulocyte-colony stimulating factor therapy improves survival in patients with hepatitis b virus-associated acute-on-chronic liver failure. World J Gastroenterol 2013; 19: 1104- 10. 10.3748/wjg.v19.i7.1104 23467275 PMC3581999 · DOI
  19. [21]Kucia M Ratajczak J Reca R Tissue-specific muscle, neural and liver stem/progenitor cells reside in the bone marrow, respond to an SDF-1 gradient and are mobilized into peripheral blood during stress and tissue injury. Blood Cells Mol Dis 2004; 32: 52- 7. 10.1016/j.bcmd.2003.09.025 14757413 · DOI
  20. [22]Kollet O Shivtiel S Chen YQ HGF, SDF-1, and MMP-9 are involved in stress-induced human cd34+ stem cell recruitment to the liver. J Clin Invest 2003; 112: 160- 9. 10.1172/JCI17902 12865405 PMC164291 · DOI
  21. [23]Lehwald N Duhme C Wildner M Hgf and sdf-1-mediated mobilization of cd133+ BMSC for hepatic regeneration following extensive liver resection. Liver Int 2014; 34: 89- 101. 10.1111/liv.12195 23701640 · DOI
  22. [24]Salama H Zekri AR Zern M Autologous hematopoietic stem cell transplantation in 48 patients with end-stage chronic liver diseases. Cell Transplant 2010; 19: 1475- 86. 10.3727/096368910X514314 20587151 · DOI
  23. [25]Gordon MY Levicar N Pai M Characterization and clinical application of human cd34+ stem/progenitor cell populations mobilized into the blood by granulocyte colony-stimulating factor. Stem Cells 2006; 24: 1822- 30. 10.1634/stemcells.2005-0629 16556705 · DOI
  24. [26]Zhang L Kang W Lei Y Granulocyte colony-stimulating factor treatment ameliorates liver injury and improves survival in rats with d-galactosamine-induced acute liver failure. Toxicol Lett 2011; 204: 92- 9. 10.1016/j.toxlet.2011.04.016 21550386 · DOI
  25. [27]Spahr L Lambert JF Rubbia-Brandt L Granulocyte-colony stimulating factor induces proliferation of hepatic progenitors in alcoholic steatohepatitis: A randomized trial. Hepatology 2008; 48: 221- 9. 10.1002/hep.22317 18537187 · DOI
  26. [28]Newsome PN Fox R King AL Granulocyte colony-stimulating factor and autologous cd133-positive stem-cell therapy in liver cirrhosis (realistic): An open-label, randomised, controlled phase 2 trial. Lancet Gastroenterol Hepatol 2018; 3: 25- 36. 10.1016/S2468-1253(17)30326-6 29127060 PMC5738975 · DOI · Paper page
  27. [29]Bai YQ Yang YX Yang YG Outcomes of autologous bone marrow mononuclear cell transplantation in decompensated liver cirrhosis. World J Gastroenterol 2014; 20: 8660- 6. 10.3748/wjg.v20.i26.8660 25024623 PMC4093718 · DOI
  28. [30]Terai S Ishikawa T Omori K Improved liver function in patients with liver cirrhosis after autologous bone marrow cell infusion therapy. Stem Cells 2006; 24: 2292- 8. 10.1634/stemcells.2005-0542 16778155 · DOI
  29. [31]Verma N Singh A Singh V. Haematopoietic stem cells in cirrhosis. Lancet Gastroenterol Hepatol 2018; 3: 298. 10.1016/S2468-1253(18)30041-4 29644972 · DOI
  30. [32]Theise ND Nimmakayalu M Gardner R Liver from bone marrow in humans. Hepatology 2000; 32: 11- 6. 10.1053/jhep.2000.9124 10869283 · DOI · Paper page
  31. [33]Wang X Willenbring H Akkari Y Cell fusion is the principal source of bone-marrow-derived hepatocytes. Nature 2003; 422: 897- 901. 10.1038/nature01531 12665832 · DOI
  32. [34]Vassilopoulos G Wang PR Russell DW. Transplanted bone marrow regenerates liver by cell fusion. Nature 2003; 422: 901- 4. 10.1038/nature01539 12665833 · DOI
  33. [35]Fujino H Hiramatsu H Tsuchiya A Human cord blood cd34+ cells develop into hepatocytes in the livers of nod/scid/gamma(c)null mice through cell fusion. Faseb J 2007; 21: 3499- 510. 10.1096/fj.06-6109com 17576850 · DOI
  34. [36]Harris RG Herzog EL Bruscia EM Lack of a fusion requirement for development of bone marrow-derived epithelia. Science 2004; 305: 90- 3. 10.1126/science.1098925 15232107 · DOI
  35. [37]Tang J Xie Q Pan G Mesenchymal stem cells participate in angiogenesis and improve heart function in rat model of myocardial ischemia with reperfusion. Eur J Cardiothorac Surg 2006; 30: 353- 61. 10.1016/j.ejcts.2006.02.070 16829080 · DOI
  36. [38]Chen Z Chua CC Ho YS Overexpression of bcl-2 attenuates apoptosis and protects against myocardial i/r injury in transgenic mice. Am J Physiol Heart Circ Physiol 2001; 280: H2313- 20. 10.1152/ajpheart.2001.280.5.H2313 11299236 · DOI
  37. [39]Pai M Zacharoulis D Milicevic MN Autologous infusion of expanded mobilized adult bone marrow-derived cd34+ cells into patients with alcoholic liver cirrhosis. Am J Gastroenterol 2008; 103: 1952- 8. 10.1111/j.1572-0241.2008.01993.x 18637092 · DOI
  38. [40]Tao YC Wang ML Chen EQ Stem cells transplantation in the treatment of patients with liver failure. Curr Stem Cell Res Ther 2018; 13: 193- 201. 10.2174/1574888X13666180105123915 29303079 · DOI
  39. [42]Wang D Zhang H Liang J Effect of allogeneic bone marrow-derived mesenchymal stem cells transplantation in a polyi:C-induced primary biliary cirrhosis mouse model. Clin Exp Med 2011; 11: 25- 32. 10.1007/s10238-010-0105-6 20661620 · DOI
  40. [43]Zhang Y Cai W Huang Q Mesenchymal stem cells alleviate bacteria-induced liver injury in mice by inducing regulatory dendritic cells. Hepatology 2014; 59: 671- 82. 10.1002/hep.26670 23929707 PMC4298763 · DOI
  41. [44]Peng L Xie DY Lin BL Autologous bone marrow mesenchymal stem cell transplantation in liver failure patients caused by hepatitis b: Short-term and long-term outcomes. Hepatology 2011; 54: 820- 8. 10.1002/hep.24434 21608000 · DOI
  42. [46]Kharaziha P Hellstrom PM Noorinayer B Improvement of liver function in liver cirrhosis patients after autologous mesenchymal stem cell injection: A phase i-ii clinical trial. Eur J Gastroenterol Hepatol 2009; 21: 1199- 205. 10.1097/MEG.0b013e32832a1f6c 19455046 · DOI · Paper page
  43. [48]Salama H Zekri AR Medhat E Peripheral vein infusion of autologous mesenchymal stem cells in Egyptian HCV-positive patients with end-stage liver disease. Stem Cell Res Ther 2014; 5: 70. 10.1186/scrt459 24886681 PMC4097846 · DOI
  44. [49]Li YH Xu Y Wu HM Umbilical cord-derived mesenchymal stem cell transplantation in hepatitis b virus related acute-on-chronic liver failure treated with plasma exchange and entecavir: A 24-month prospective study. Stem Cell Rev Rep 2016; 12: 645- 53. 10.1007/s12015-016-9683-3 27687792 · DOI
  45. [50]Shi M Zhang Z Xu R Human mesenchymal stem cell transfusion is safe and improves liver function in acute-on-chronic liver failure patients. Stem Cells Transl Med 2012; 1: 725- 31. 10.5966/sctm.2012-0034 23197664 PMC3659658 · DOI
  46. [51]Kern S Eichler H Stoeve J Comparative analysis of mesenchymal stem cells from bone marrow, umbilical cord blood, or adipose tissue. Stem Cells 2006; 24: 1294- 301. 10.1634/stemcells.2005-0342 16410387 · DOI · Paper page
  47. [52]Zhang Z Lin H Shi M Human umbilical cord mesenchymal stem cells improve liver function and ascites in decompensated liver cirrhosis patients. J Gastroenterol Hepatol 2012; 27 Suppl 2: 112- 20. 10.1111/j.1440-1746.2011.07024.x 22320928 · DOI · Paper page
  48. [53]Guo G Zhuang X Xu Q Peripheral infusion of human umbilical cord mesenchymal stem cells rescues acute liver failure lethality in monkeys. Stem Cell Res Ther 2019; 10: 84. 10.1186/s13287-019-1184-2 30867056 PMC6417089 · DOI
  49. [54]Gilsanz C Aller MA Fuentes-Julian S Adipose-derived mesenchymal stem cells slow disease progression of acute-on-chronic liver failure. Biomed Pharmacother 2017; 91: 776- 87. 10.1016/j.biopha.2017.04.117 28501004 · DOI
  50. [55]Gazdic M Arsenijevic A Markovic BS Mesenchymal stem cell-dependent modulation of liver diseases. Int J Biol Sci 2017; 13: 1109- 17. 10.7150/ijbs.20240 29104502 PMC5666326 · DOI
  51. [56]Xagorari A Siotou E Yiangou M Protective effect of mesenchymal stem cell-conditioned medium on hepatic cell apoptosis after acute liver injury. Int J Clin Exp Pathol 2013; 6: 831- 40. 23638214 PMC3638093
  52. [57]Zhu X He B Zhou X Effects of transplanted bone-marrow-derived mesenchymal stem cells in animal models of acute hepatitis. Cell Tissue Res 2013; 351: 477- 86. 10.1007/s00441-012-1524-3 23143676 · DOI
  53. [58]Trounson A McDonald C. Stem cell therapies in clinical trials: Progress and challenges. Cell Stem Cell 2015; 17: 11- 22. 10.1016/j.stem.2015.06.007 26140604 · DOI
  54. [59]Doi Y Sugahara H Yamamoto K Immune-mediated peripheral neuropathy occurring simultaneously with recurrent graft-versus-host disease after allogenic hematopoietic stem cell transplantation. Leuk Res 2012; 36: e63- 5. 10.1016/j.leukres.2011.11.025 22177946 · DOI
  55. [60]Sethe S Scutt A Stolzing A. Aging of mesenchymal stem cells. Ageing Res Rev 2006; 5: 91- 116. 10.1016/j.arr.2005.10.001 16310414 · DOI
  56. [61]Mamidi MK Dutta S Bhonde R Allogeneic and autologous mode of stem cell transplantation in regenerative medicine: Which way to go? Med Hypotheses 2014; 83: 787- 91. 10.1016/j.mehy.2014.10.010 25456787 · DOI
  57. [62]Ding DC Chang YH Shyu WC Human umbilical cord mesenchymal stem cells: A new era for stem cell therapy. Cell Transplant 2015; 24: 339- 47. 10.3727/096368915X686841 25622293 · DOI
  58. [63]Schu S Nosov M O'Flynn L Immunogenicity of allogeneic mesenchymal stem cells. J Cell Mol Med 2012; 16: 2094- 103. 10.1111/j.1582-4934.2011.01509.x 22151542 PMC3822979 · DOI
  59. [64]Griffin MD Ryan AE Alagesan S Anti-donor immune responses elicited by allogeneic mesenchymal stem cells: What have we learned so far? Immunol Cell Biol 2013; 91: 40- 51. 10.1038/icb.2012.67 23207278 · DOI
  60. [65]Zekri AR Salama H Medhat E The impact of repeated autologous infusion of haematopoietic stem cells in patients with liver insufficiency. Stem Cell Res Ther 2015; 6: 118. 10.1186/s13287-015-0106-1 26062731 PMC4482193 · DOI
  61. [66]Wang Q Qian S Li J Combined transplantation of autologous hematopoietic stem cells and allogenic mesenchymal stem cells increases t regulatory cells in systemic lupus erythematosus with refractory lupus nephritis and leukopenia. Lupus 2015; 24: 1221- 6. 10.1177/0961203315583541 25914407 · DOI
  62. [67]Wang N Shao Y Mei Y Novel mechanism for mesenchymal stem cells in attenuating peritoneal adhesion: Accumulating in the lung and secreting tumor necrosis factor alpha-stimulating gene-6. Stem Cell Res Ther 2012; 3: 51. 10.1186/scrt142 23217986 PMC3580481 · DOI
  63. [68]Watanabe T Kajiume T Takaue Y Decrease in circulating hematopoietic progenitor cells by trapping in the pulmonary circulation. Cytotherapy 2001; 3: 461- 6. 10.1080/146532401317248063 11953030 · DOI
  64. [69]Eggenhofer E Benseler V Kroemer A Mesenchymal stem cells are short-lived and do not migrate beyond the lungs after intravenous infusion. Front Immunol 2012; 3: 297. 10.3389/fimmu.2012.00297 23056000 PMC3458305 · DOI · Paper page
  65. [70]Sun L Fan X Zhang L Bone mesenchymal stem cell transplantation via four routes for the treatment of acute liver failure in rats. Int J Mol Med 2014; 34: 987- 96. 10.3892/ijmm.2014.1890 25110277 PMC4152144 · DOI
  66. [71]Truong NH, Nguyen NH, Le TV, et al. Comparison of the treatment efficiency of bone marrow-derived mesenchymal stem cell transplantation via tail and portal veins in ccl4-induced mouse liver fibrosis. Stem Cells Int 2016;2016:5720413. PMC4709782 26839564
  67. [72]Deng Q Cai T Zhang S Autologous peripheral blood stem cell transplantation improves portal hemodynamics in patients with hepatitis b virus-related decompensated cirrhosis. Hepat Mon 2015; 15: e32498. 10.5812/hepatmon.32498 26977164 PMC4774339 · DOI · Paper page
  68. [73]Sharma M Rao PN Sasikala M Autologous mobilized peripheral blood cd34(+) cell infusion in non-viral decompensated liver cirrhosis. World J Gastroenterol 2015; 21: 7264- 71. 10.3748/wjg.v21.i23.7264 26109814 PMC4476889 · DOI
  69. [74]Mohamadnejad M Namiri M Bagheri M Phase 1 human trial of autologous bone marrow-hematopoietic stem cell transplantation in patients with decompensated cirrhosis. World J Gastroenterol 2007; 13: 3359- 63. 10.3748/wjg.v13.i24.3359 17659676 PMC4172717 · DOI · Paper page
  70. [75]Mohamadnejad M Alimoghaddam K Mohyeddin-Bonab M Phase 1 trial of autologous bone marrow mesenchymal stem cell transplantation in patients with decompensated liver cirrhosis. Arch Iran Med 2007; 10: 459- 66. 17903050

Cited by

Sorted by citations

See all 15

Metadata

Authors
Tao, Y.-C., & Chen, E.-Q.
Affiliations
Sichuan University (CN)
Corresponding author
Chen, En-Qiang
ORCID
Chen, En-Qiang
Venue
Annals of Translational Medicine
Publisher
AME Publishing Company
Published
2020-04
Volume
8
Issue
8
Pages
564-564
ISSN
  • 2305-5839 (ISSN-L)
  • 2305-5847
DOI
10.21037/atm.2020.03.153
PMC
PMC7347777
OpenAlex
W3016132356
Cited by
15
References
5
Citations by year
2025: 5 · 2024: 2 · 2023: 3 · 2021: 4 · 2020: 1
FWCI
0.29
Type
journal article
Language
en
Open access
Licence
cc-by-nc-nd
Locations
  • Annals of Translational Medicine (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
Funders
Department of Science and Technology of Sichuan Province (2019YFS0209)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Mesenchymal stem cell research
  • Health Sciences › Medicine › Hematology › Hematopoietic Stem Cell Transplantation
  • Health Sciences › Medicine › Hepatology › Liver physiology and pathology
Keywords
end-stage liver disease, stem cell therapy, multipotent stem cells, hematopoietic stem cells, mesenchymal stem cells, bone marrow-derived stem cells, granulocyte colony-stimulating factor, stem cell transplantation, liver transplantation alternatives

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review